A Long-Term Follow-Up Study of Participants Exposed to REACT

Description

The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).

Conditions

Diabetic Kidney Disease, Chronic Kidney Diseases

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).

A Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy From Studies RMCL-002, REGEN-003, REGEN-004

A Long-Term Follow-Up Study of Participants Exposed to REACT

Condition
Diabetic Kidney Disease
Intervention / Treatment

-

Contacts and Locations

Meridian

Boise Kidney & Hypertension Institute, Meridian, Idaho, United States, 83642

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.
  • * The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.

Ages Eligible for Study

30 Years to 80 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Prokidney,

Study Director, STUDY_DIRECTOR, Prokidney

Study Record Dates

2028-03